Cyclin-dependent kinase inhibitors: A survey of the recent patent literature

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 6, 2005, Pages 675-703

  Pevarello, Paolo ^a   Villa, Manuela ^a  

^a Nerviano Medical Sciences ^*

Author keywords

Cancer treatment; Cell cycle; Cyclin dependent kinase (CDK); Inhibitor

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CARBAZOLE DERIVATIVE; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FLAVOPIRIDOL; GEMCITABINE; IMATINIB; IMIDAZOLE DERIVATIVE; IMIDAZOPYRAZINE DERIVATIVE; INDAZOLE DERIVATIVE; INDIRUBIN; INDOLE DERIVATIVE; INDOLIZINE DERIVATIVE; MITOXANTRONE; OLOMOUCINE; OXAZOLE DERIVATIVE; OXINDOLE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PURVALANOL; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRAZOLONE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RETINOID; ROSCOVITINE; SEMICARBAZIDE DERIVATIVE; THIAZOLE DERIVATIVE; UREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DISEASE MODEL; DRUG INDUSTRY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HEALTH SURVEY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATENT; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 21244450397     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.6.675     Document Type: Review

References (28)

1. SHERR CJ: Cancer cell cycles. Science (1996) 274:1672-1677.
2. ZHAI S, SENDEROWICZ AM, SAUSVILLE EA, FIGG WD: Flavopiridol, a novel cychn-dependent kinase inhibitor, in clinical development. Ann. Pharmacother. (2002) 36:905-911.
3. SENDEROWICZ AM: Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol. Ther. (2003) 2(4, Suppl. 1):S84-S95.
4. TETSU O, MCCORMICK F: Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell (2003) 3:233-245.
5. MALUMBRES M, SOTILLO R, SANTAMARIA D et al.: Mammalian cells cycle without the D-type cyclin-dependent kinases CDK4 mid CDK6. Cell (2004) 118(4):493-504.
6. FISCHER PM, ENDICOTT J, MEIJER L: Cyclin-dependent kinase inhibitors. Prog. Cell Cycle Res. (2003) 5:235-248.
7. REN S, ROLLINS BJ: Cyclin C/CDK3 promotes Rb-dependenr G0 exit. Cell (2004) 117:239-251.
8. DYNLACHT B: Regulation of transcription during the cell cycle. Transcript. Fact. (2001):85-112.
9. DE FALCO G, GIORDANO A: CDK9: from basal transcription to cancer and AIDS. Cancer Biol. Therap. (2002) 1(4):342-347.
10. CRUZ JC, TSAI LH: CDK5 deregulation in the pathogenesis of Alzheimer's disease. Curr. Opin. Neurobiol. (2004) 14(3):390-394.
11. BYTH KF, CULSHAW JD, GREEN S, OAKES SE, THOMAS AP: Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:2245-2248.
12. MISRA RN, XIAO HY, KIM KS et al.: (Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl] methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. (2004) 47(7):1719-1728.
13. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett. (2003) 13(6):1133-1136.
14. YUE EW, HIGLEY CA, DIMEO SV et al.: Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3. J. Med. Chem. (2002) 45(24):5233-5248.
15. HELAL CJ, SANNER MA, COOPER CB et al.: Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg. Med. Chem. Lett. (2004) 14:5521-5525.
16. PEVARELLO P, BRASCA MG, AMICI R et al.: 3-Aminopyrazole inhibitors of CDK2/Cyclin A as antitumor agents. 1. Lead finding. J. Med. Chem. (2004) 47:3367-3380.
17. D'ALESSIO R, BARGIOTTI A, METZ S et al.: Benzodipyrazoles: a new class of potent CDK2 inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(5):1315-1319.
18. MOSHINSKY DJ, BELLAMACINA CR, BOISVERT DC et al.: SU 9516: Biochemical analysis of Cdk inhibition and crystal structure in complex with CDK2. Biochem. Biophys. Res. Comm. (2003) 310(3):1026-1031.
19. TANG J, SHEWCHUCK LM, SATO H, HASEGAWA M, WASHIO Y, NISHIGAKI N: Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis. Bioorg. Med. Chem. Lett. (2003) 13:2985-2988.
20. ENGLER TA, FURNESS K, MALHOTRA S et al.: Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. Bioorg. Med. Chem. Lett. (2003) 13(14):2261-2267.
21. NAGAMATSU T, YAMASAKI H: General syntheses of 1-alkyltoxoflavin and 8-alkylfervenulin derivatives of biological significance by the regioselective alkylation of reumycin derivatives and the rates of transalkylation from 1-alkyltoxoflavins into nucleophiles. J. Chem. Soc. Perkin Trans. 1 (2001):130-137.
22. HONMA T, HAYASHI K, AOYAMA T et al.: Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. (2001) 44(26):4615-4627.
23. SKEHAN P, STORENG R, SCUDIERO D et al.: New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. (1990) 82:1107-1112.
24. WANG S, MEADES C, WOOD G et al.: 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J. Med. Chem. (2004) 47(7):1662-1675.
25. 1H-pyrrol-3-yl)pyrimidine CDK inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(16):4237-4240.
26. BILODEAU MT, BALITZA AE, KOESTER TJ et al.: Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the herg ion channel. J. Med. Chem. (2004) 47(25):6363-6372.
27. METTEY Y, GOMPEL M, THOMAS V et al.: Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. (2003) 46(2):222-236.
28. GONZALEZ T, SEOANE M, CAAMANO P, VINUELA J, DOMINGUEZ F, ZALVIDE J et al.: Inhibition of CDK4 activity enhances translation of p27kip1 in quiescent Rb-negative cells. J. Biol. Chem. (2003) 15(11):12689-12695.